Move will add surgical imaging system to product portfolio.
Carestream Health and Ziehm Imaging announced a partnership on April 19 that will add a mobile C-arm to the Carestream product portfolio.
The mobile C-arm, known as the Ziehm Vision RFD C-arm is a surgical imaging system that will expand Carestream’s mobile and fluoroscopic capabilities.
“The partnership with Carestream confirms Ziehm Imaging’s industry-leading technology,” said Nelson Mendes, president and chief executive officer of Orthoscan and Ziehm Imaging, Inc. “As a result of this partnership, we’re able to provide Carestream and its customers with one of the most innovate C-arms on the market.”
The Vision RFD C-arm is outfitted with a 25-kilowatt generator in either a 20.5 x 20.5 cm or 31 cm x 31 cm field-of-view flat-panel CMOS digital detector. Not only does it allow for general surgical applications, but it can also provide for vascular, cardiac, spine ortho-trauma, and pain management procedural work.
According to company officials, the product’s Advanced Active Cooling system can extend case times beyond what is possible with traditional air-cooled systems. Its graphical interface is intuitive and can reduce training times and increase productivity, they said. By using SmartDose, it also reduces exposure.
Vision RFD systems will be available in the United States and Canada this year with sale and service available through Carestream.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation
March 29th 2024In a cohort of patients with invasive breast cancer and tumor sizes ranging between 0.3 to 9 cm, image-guided cryoablation was associated with a 10 percent recurrence rate at 16 months, according to research recently presented at the Society of Interventional Radiology (SIR) conference.